Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related...
2 insider purchases on record · latest filing 2026-05-22.
Insiders have also filed 2 sale transactions at KLRS.